VEGFA and hypertensive disorder: In a metastatic breast cancer study involving patients being treated with paclitaxel and bevacizumab (E2100 trial), SNP analysis demonstrated that the VEGF-2578 AA and VEGF-1154 AA genotypes predicted an improved median overall survival, whereas the VEGF-634 CC and VEGF-1498 TT variants predicted protection from grades 3-4 hypertension in the combination treatment arm [149].